XBIO earnings analysis
What we found in XBIO's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Xenetic Biosciences, Inc. reported revenue of approximately $806,923 for Q1 2026, indicating a 36% increase from $593,261 in Q1 2025. The net loss for the quarter improved to $(456,382) compared to $(903,141) in the prior year, resulting in an EPS of $(0.20) versus $(0.59). Management highlights a strategic review process and a necessity for additional capital funding going forward.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Up 36% YoY
- Revenue increased to $806,923 in Q1 2026 from $593,261 in Q1 2025.
- Net Loss Narrowed by 49.5%
- Net loss improved to $(456,382) compared to $(903,141) for the same quarter last year.
- EPS Improved Significantly
- Diluted EPS improved to $(0.20) from $(0.59) year over year.
- Lower R&D Expenses
- R&D expenses decreased by 24.8% to $661,443 from $879,029 in Q1 2025.
- Cash Position Remains Strong
- Cash balances decreased slightly to $7,347,255 from $7,883,632 at period end.
- Operating Loss Decrease
- Loss from operations was reduced by 46.7%, to $(502,117) from $(942,409) in Q1 2025.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Need for Future Capital
- Management indicated the need for additional capital to support long-term initiatives.
- Ongoing Strategic Review
- Uncertainty regarding the outcomes of the strategic review process could affect operations.
- Geopolitical Exposure
- Management noted potential impacts from geopolitical events on financial conditions.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.2
What they said about what is next.
Outlook deferred to earnings press release / call.
The filing reads better than the one before it.
What came before.
- 10-K · April 24, 2026
- The 10-K/A adds Part III governance, compensation and related-party disclosures and shows improvement in 2025 operating performance versus 2024 but continued losses and material related‑party activity. Net loss narrowed…
- 10-K · March 12, 2026
- Xenetic (XBIO) positions itself as an early‑stage immuno‑oncology company focused on advancing a systemic DNase platform toward a first‑in‑human, multicenter, dose‑escalation and dose‑expansion study of IV rhDNase I…
- 10-Q · May 13, 2025
- Xenetic reported Q1 2025 revenue of $593,261, up $82,444 (16.1%) from Q1 2024 revenue of $510,817, and delivered an EPS loss of $(0.59) versus $(0.78) in Q1 2024 (improvement of $0.19). Operating loss remains large:…
- 10-K · March 18, 2025
- Xenetic Biosciences is an early-stage immuno-oncology company focused on advancing a systemic DNase program (IV rhDNase I) toward a first-in-human, multicenter dose-escalation and dose-expansion study in locally…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing XBIO makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever